Drugs / BG-C477
last change Oct 2024 re-read 2 minutes ago

BG-C477

Developed for
cancer
Investigated by
BeOne Medicines

Trials 1 · a red edge is where a trial was stopped

2025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06596473 Oct 2024 → Dec 2027 expected cancer BeOne Medicines Recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as BG-C477 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06596473
Route Intravenous “Administered intravenously.” NCT06596473